Although 68Ga-PSMA PET/CT is a technique that has only recentlybeen applied in clinical settings, despite its high cost,68Ga-PSMA PET/CT shows great promise as a tool in the clinicalmanagement of patients with kidney and prostate cancer, especially in thosewith prostate cancer whose PSA levels are elevated even after treatment. Here, FOLH1 is linked to prostate carcinoma.